Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively, Friday after a report that the Trump administration plans to link the deaths of 25 children to COVID vaccines. Trump health officials ...

Daniel Payne reports on how the health industry and Washington influence and impact each other. He joined STAT in 2025 after covering health care at POLITICO. You can reach Daniel on Signal at danielp ...

Matthew Herper covers medical innovation — both its promise and its perils. Amid all the hand-shaking and back-patting, it was perhaps the word “friendship” that stood out the most when the CEO of ...

Sales of Pfizer's COVID-19 products have collapsed. Thanks to heavy investment fueled by COVID-related revenue, Pfizer has a big pipeline of new potential blockbuster drugs. Cancer treatments Pfizer ...